ViferaXS

ViferaXS – Pioneering Peptide-Based T Cell Activators

About Us
ViferaXS is a biotechnology company dedicated to developing next-generation, peptide-based T cell activators. Our mission is to harness the power of the immunopeptidome and innovative adjuvant technologies to activate the body’s own immune system against malignant cells, offering patients safe, effective, and long-lasting treatment options.

Our Science
At the core of ViferaXS is a proprietary immunopeptidome-driven platform combined with our unique XS15 adjuvant. This approach enables the design of highly specific, personalized or semi-personalized peptide-based T cell activators that effectively activate tumor-targeting T cells. By focusing on tumor-associated antigens directly identified from patients, our platform provides unparalleled precision and clinical relevance.

Pipeline
ViferaXS is advancing a robust pipeline addressing both hematologic and solid tumors:

• CLL (Chronic Lymphocytic Leukemia): Phase II program to prevent disease progression in early-stage patients.

• AML (Acute Myeloid Leukemia): Development of targeted peptide vaccines for high-risk patients.

• FLC (Fibrolamellar Carcinoma): First-in-class immunotherapy approach for this rare liver cancer.

• Prostate Cancer: Preclinical development of a peptide-based therapeutic vaccine.

• Exploratory programs: Future expansion into HCC, TNBC, and other solid tumors.

Vision & Impact
Cancer remains one of the greatest medical challenges of our time. At ViferaXS, we believe vaccines can transform oncology by shifting treatment paradigms from late-stage, toxic interventions toward early, immune-mediated control of disease. Our goal is to deliver therapies that are not only clinically effective but also accessible, scalable, and patient-friendly.

Looking Ahead
ViferaXS is actively preparing for its next stage of growth, including regulatory interactions, clinical trial execution, and strategic partnerships. By combining cutting-edge science, a strong clinical network, and an ambitious vision, we are positioning ourselves at the forefront of therapeutic cancer immunotherapy.